{
  "kind": "treatment",
  "slug": "midazolam-versed",
  "type": "benzodiazepine",
  "name": "Midazolam (Versed)",
  "summary": "A short-acting benzodiazepine used for sedation, anesthesia, seizure control, and acute agitation.",
  "description": "Midazolam is a short-acting benzodiazepine that enhances the effects of gamma-aminobutyric acid (GABA) at the GABA-A receptor, producing sedative, anxiolytic, muscle relaxant, and anticonvulsant effects. It is widely used for procedural sedation, induction of anesthesia, acute seizure management, and severe agitation. Available in oral, injectable, and intranasal forms.",
  "category": "medications/benzodiazepines",
  "tags": [
    "benzodiazepine",
    "sedative",
    "anxiolytic",
    "anticonvulsant",
    "anesthetic"
  ],
  "metadata": {
    "drug_classes": [
      "Benzodiazepine",
      "Sedative-Hypnotic"
    ],
    "therapeutic_categories": [
      "Anesthesia",
      "Seizure Disorders",
      "Anxiety",
      "Critical Care"
    ],
    "mechanism_categories": [
      "GABA"
    ],
    "administration_routes": [
      "Oral",
      "Injection",
      "Inhaled"
    ],
    "prescription_status": "Prescription Required",
    "controlled_substance": true,
    "generic_available": true,
    "brand_names": [
      "Versed",
      "Dormicum"
    ],
    "dea_schedule": "IV",
    "fda_pregnancy_category": "D",
    "age_groups": [
      "Pediatric",
      "Adult",
      "Geriatric"
    ],
    "treatment_duration": [
      "Short-term",
      "Acute use"
    ],
    "specialty_areas": [
      "Anesthesiology",
      "Emergency Medicine",
      "Critical Care",
      "Neurology",
      "Psychiatry"
    ],
    "fda_approval_year": 1985
  },
  "clinical_metadata": {
    "primary_indications": [
      "Other"
    ],
    "off_label_uses": [
      "Severe anxiety episodes",
      "Palliative sedation"
    ],
    "contraindications": [
      "Acute narrow-angle glaucoma",
      "Severe respiratory depression without ventilatory support",
      "Hypersensitivity to benzodiazepines"
    ],
    "monitoring_required": [
      "Respiratory rate and oxygen saturation",
      "Blood pressure",
      "Level of consciousness"
    ],
    "efficacy_rating": {
      "sedation": 5,
      "seizure_control": 4,
      "anxiety": 3
    }
  },
  "search_metadata": {
    "searchable_terms": [
      "midazolam",
      "versed",
      "benzodiazepine",
      "sedative",
      "procedural sedation",
      "anesthetic"
    ],
    "synonyms": [
      "midazolam hydrochloride"
    ],
    "common_misspellings": [
      "midazolan",
      "midazalam",
      "versed"
    ]
  },
  "sections": [
    {
      "type": "indications",
      "items": [
        "Procedural sedation",
        "Induction and maintenance of anesthesia",
        "Status epilepticus",
        "Acute agitation",
        "Premedication for surgery"
      ]
    },
    {
      "type": "mechanism",
      "text": "Enhances GABA-A receptor activity by increasing the frequency of chloride channel opening, leading to neuronal hyperpolarization and CNS depression."
    },
    {
      "type": "dosing",
      "adult": {
        "procedural_sedation": "Initial: 1–2.5 mg IV slowly over 2 minutes; may repeat in small increments as needed",
        "status_epilepticus": "10 mg intranasal or buccal once; may repeat in 10 minutes if seizures persist",
        "premedication": "0.07–0.08 mg/kg IM 30–60 minutes before procedure"
      },
      "pediatric": {
        "procedural_sedation": "0.05–0.1 mg/kg IV (max 2 mg per dose)",
        "status_epilepticus": "0.2 mg/kg intranasal or buccal (max 10 mg)"
      },
      "geriatric": "Lower initial doses recommended; titrate cautiously",
      "hepatic_impairment": "Use with caution; reduced clearance",
      "renal_impairment": "Use with caution in prolonged infusions"
    },
    {
      "type": "dosage_forms",
      "items": [
        "Injectable solution: 1 mg/mL, 5 mg/mL",
        "Oral syrup: 2 mg/mL",
        "Intranasal solution: 5 mg/0.1 mL"
      ]
    },
    {
      "type": "onset_duration",
      "text": "Onset: 1–5 minutes IV; Duration: 1–2 hours after single dose."
    },
    {
      "type": "adverse_effects",
      "common": [
        "drowsiness",
        "dizziness",
        "amnesia",
        "ataxia"
      ],
      "less_common": [
        "nausea",
        "vomiting",
        "headache"
      ],
      "serious": [
        "respiratory depression",
        "hypotension",
        "paradoxical agitation",
        "cardiac arrest"
      ]
    },
    {
      "type": "warnings",
      "black_box": "Concomitant use with opioids may result in profound sedation, respiratory depression, coma, and death.",
      "other": [
        "Monitor respiratory and cardiovascular function continuously during administration",
        "Avoid in patients with severe respiratory insufficiency unless mechanical ventilation is available"
      ]
    },
    {
      "type": "interactions",
      "items": [
        {
          "with": "Opioids",
          "risk": "Respiratory depression",
          "action": "Avoid or use with extreme caution"
        },
        {
          "with": "Other CNS depressants",
          "risk": "Enhanced sedation",
          "action": "Dose adjustment and monitoring required"
        },
        {
          "with": "CYP3A4 inhibitors",
          "risk": "Increased midazolam levels",
          "action": "Consider dose reduction"
        }
      ]
    },
    {
      "type": "monitoring",
      "items": [
        "Respiratory function",
        "Blood pressure",
        "Level of sedation",
        "Heart rate"
      ]
    },
    {
      "type": "special_populations",
      "pregnancy": "Use only if benefits outweigh risks; potential for neonatal respiratory depression",
      "lactation": "Excreted in breast milk; avoid or monitor infant",
      "pediatrics": "Safe when dosed appropriately; widely used for seizures and sedation",
      "geriatrics": "Increased sensitivity; lower doses required"
    },
    {
      "type": "tapering",
      "text": "Not usually required for single or short-term use; prolonged infusions should be tapered gradually to avoid withdrawal."
    },
    {
      "type": "clinical_notes",
      "items": [
        "Preferred benzodiazepine for rapid sedation in procedural settings due to short duration",
        "Intranasal form is widely used for community management of seizures",
        "Marked anterograde amnesia can occur"
      ]
    },
    {
      "type": "references",
      "items": [
        {
          "label": "Versed Prescribing Information",
          "url": "https://www.accessdata.fda.gov/"
        },
        {
          "label": "Midazolam Intranasal Dosing Guidelines",
          "url": "https://www.epilepsy.com/"
        }
      ]
    }
  ],
  "seo": {
    "title": "Midazolam (Versed): Sedative and Seizure Management",
    "description": "Midazolam is a short-acting benzodiazepine used for sedation, anesthesia induction, acute agitation, and seizure control, available in injectable and intranasal forms."
  }
}
